The benefit of exclusive nocturnal administration of a levodopa-carbidopa intestinal infusion for severe refractory sleep behavior disorder in Parkinson’s disease
Objective: Treatment by continuous diurnal intestinal infusion of levodopa is effective in improving sleep quality in Parkinson's disease (PD), but its use exclusively at night…Levodopa Carbidopa Intestinal Gel in Patients with Deep Brain Stimulation in Parkinson’s disease- First case series from Middle-East Region
Objective: The objective is to report unique and challenging cases, who had successful control of Parkinson’s disease (PD) symptoms with combination therapy of Deep Brain…Clinical and risk profiles of Parkinson’s disease from a large pan-India cohort: interim observations of the GAP-India study
Objective: To create a pan-Indian clinical repository of Parkinson’s Disease (PD). Background: The genetic risk for PD in India is unknown. The Luxembourg-German India Alliance…OPICAPONE ADD-ON THERAPY IN LEVODOPA-CARBIDOPA INTESTINAL GEL INFUSION: which patient might benefit the most?
Objective: To explore the benefit of Opicapone (OPC) add-on to levodopa-carbidopa intestinal gel (LCIG) in different phenotypes of Parkinson’s Disease (PD) patients. Background: LCIG monotherapy…A case of levodopa responsive parkinsonism due to methanol toxicity, an impact of COVID-19 crisis
Objective: To report the clinical course of secondary parkinsonism due to methanol toxicity with good levodopa responsiveness in the background of COVID-19 crisis. Background: The…Efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease patients with motor fluctuations: a multicenter randomized open-label cross-over trial
Objective: This study aimed to assess the efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease (PD) patients with motor fluctuation. Background: Delayed…Effect of levodopa-carbidopa intestinal gel on lower urinary tract symptoms in Parkinson’s disease: an Urodynamic study
Objective: Here we report urodynamic results before and six months after LCIG treatment in PD patients suffering from LUTS. Background: Dopaminergic transmission plays a key…Variability of Plasma Levodopa Conveniently Reduced by More Frequent Administration of Smaller Doses of Carbidopa/Levodopa Using a Novel Functionally Scored Formulation
Objective: To evaluate the pharmacokinetics (PK) of 25/100 mg carbidopa (CD)/levodopa (LD) compared to half that amount given twice as often using a new, deeply…Systematic Literature Review of Key Outcomes Used to Assess Adjunctive Treatments for Parkinson’s Disease
Objective: Understand key efficacy outcomes used to assess adjunctive treatments to carbidopa/levodopa (CD/LD) for Parkinson’s disease (PD). Background: CD/LD is widely considered the most effective…Availability and accessibility of medicines for patients with Parkinson’s disease in Kyrgyzstan
Objective: The aim of the study was to assess the availability and accessibility of medicines for patients with Parkinson’s disease (PD) in Kyrgyzstan. Background: After…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 57
- Next Page »